Question-and-Answer Session
Operator
Thank you. (Operator's Instructions). Our first question today comes from Tom Shrader of Rodman.
Thomas Shrader - Rodman & Renshaw
Good morning.
Alfred Mann
Good morning, Tom.
Thomas Shrader - Rodman & Renshaw
Hope you guys are enjoying the calm before the storm. So, Al, you are talking a lot about basal insulin. Is this a new molecule, is this someone else's that you like more than Lantus? Can you give us a hint of what you're talking about?
Alfred Mann
I can't really discuss it yet, Tom. It's not at a point where we can make it public, but we are looking at an interesting solution to the basalproblem.
Thomas Shrader - Rodman & Renshaw
Okay. And the trial where you try to get fasting glucose less than 100, is that 317?
Alfred Mann
No. It's 117, and the protocol, we try to get it down to under 110, but the doctors were so worried that we ended up it's under 120, but we're going to try to get as many as we can, at least with the AFRESA, to get them below 100.
Thomas Shrader - Rodman & Renshaw
And is that trial enrolling, or are you nervous that Lantus just won't let you do that trial the way you want to? Is that trial—are you going to do that with Lantus?
Thomas Mann
Is it rolling? Peter, do you want to comment?
Peter Richardson
Yes. It's actually enrolling and it's enrolling quite nicely at the present time. What we did there was we've actually gone and, after a lot of discussion with the opinion leaders, we actually changed the Lantus dosing from that which we used in '09 to allow for them to split the dose which is very commonly done in type I patients in order to try and smooth out the Lantus profile, because clearly what we've seen is that if you dose in the evening, you're really getting insufficient by 25 hours later to maintain that control.
And we want to be able to show that using Lantus in the best way we could and with the really very distinguished group of opinion leaders that we had on this study, they thought that was the appropriate way that we should approach this to show what AFRESA could really do if we got the best that we could for the basal insulin. Unfortunately, that requires twice daily dosing at the moment.
- To read the full transcript on Seeking Alpha, click here »
